Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• FLOW Analysis: Semaglutide Delivers Consistent Kidney Benefit in T2D/CKD Across CVD Status
  Semaglutide improved kidney and survival outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), including those with established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) and high total cardiovascular disease risk, according to a subgroup analysis of the FLOW trial...
• ACCEL Lite: Insights From the CADENCE Trial
  In this interview, Clyde W. Yancy MD, MACC and Mardi Gomberg-Maitland, MD, MSc, FACC discuss the CADENCE Trial (Efficacy And Safety Of Sotatercept In Combined Post-and Pre-capillary Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction).
• Managing Cardiovascular Disease in Older Adults With Cognitive Impairment: Challenges and Practical Strategies
  Older adults with cardiovascular (CV) risk factors or established cardiovascular disease (CVD) are at increased risk of cognitive impairment (CI). This risk is observed across several conditions, including hypertension, atrial fibrillation (AF), heart failure, and coronary artery disease.
• Editors' Corner | The Ongoing Challenge of Tricuspid Regurgitation
  This month's cover story offers a practical, concise review of contemporary care for patients with tricuspid regurgitation (TR). It synthesizes key lessons from clinical trials that now guide decision-making for direct tricuspid valve interventions.
• Cover Story | Tricuspid Valve Intervention: Clinical Decision-Making For Patient Selection
  For decades, cardiologists have referred to the tricuspid valve as "the forgotten valve." One reason for this neglect is that tricuspid regurgitation (TR) often goes unnoticed, explains Robert O. Bonow, MD, MACC, Distinguished Professor at Northwestern University Feinberg School of Medicine in Chicago, IL.